Treatment of MS in children

Management of relapses

• i.v. methylprednisolone, 20mg/kg/day to 30mg/kg/day (maximum 1g) for 3 to5 days

• oral methylprednisolone at a dose of 500mg for 5 days

Disease modifying therapy

Treatment goal

• reduce relapses

• disability progression,

• accrual of new MRI lesions

• no evidence of disease activity /NEDA

DMT approved for adult MS are applied in POMS

Evidence on effectiveness and safety from observational studies

Le Page E, Veillard D, Laplaud DA, et al. Oral versusintravenous high-dose methylprednisolone for treatmentof relapses in patients with multiple sclerosis (COPOU-SEP): a randomised, controlled, double-blind, non-infer-iority trial.Lancet2015

Ziemssen T, Derfuss T, de Stefano N, et al. Optimizing treatment success in multiple sclerosis.J Neurol2016; Bevan CJ, Cree BA. Disease activity free status: a new end point for a new era in multiple sclerosis clinical research?JAMA Neurol2014